US Government As Represented by the Secretary of the Army

Duke University

Children's Medical Center Corporation

Beth Israel Deaconess Medical Center, Inc.

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Janssen Vaccines & Prevention B.v.

Other

New York University

U.S. Army Medical Research and Materiel Command

Jerome H Kim

Nelson L Michael

Barton F Haynes

Dan H Barouch

Maria Grazia Pau

Stephen C Harrison

Georgia D Tomaras

Johanna Schuitemaker

Frank Tomaka

Jintanat Ananworanich

Merlin Robb

Bette T Korber

Susan Zolla-Pazner

Morgane Rolland

Huaxin Liao

Susan B Zolla-Pazner

The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.

Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use

The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1) particular, to a polyvalent vaccine for HIV-1 and to methods of making and using same.

Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage

Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens

The invention is generally directed to V1V2 immunogens.

Immunogens comprising human immunodeficiency virus V1/V2 polypeptides

The instant invention provides a means for quantitatively determining the vel of tumor suppressor gene p53 by determination of level of messenger ribonucleic acid (mRNA) of the gene in a sample when compared with a prepared standard. The assay is quantitative in that the specific number of copies of the p53 mRNA in a sample may be derived from a curve from a standard of p53 RNA. The RNA used in preparation of a standard curve to quantitate RNA is generated using a plasmid which is part of the invention. In the assay, the RNA is produced by a protein (RNA polymerase) that reads the DNA message and manufactures an RNA copy. The RNA content of the transcribed sample is determined spectrophotometrically to measure the molar concentration. With prior knowledge of the molecular weight of the transcribed RNA and using Avogadro's number, the actual number of molecules of transcripted 'control' p53 RNA can be determined

Method of measuring tumor suppressor gene p53

Growing community of inventors

Baltimore, MD, United States of America

Jerome H Kim